INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Total Non-Current Liabilities History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹0.56 Cr | ₹2.29 Cr | ₹3.59 Cr | ₹2.09 Cr | ₹4.07 Cr |
What is the latest Total Non-Current Liabilities ratio of INDO US BIOTECH ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹0.56 Cr |
| Mar2025 | ₹2.29 Cr |
| Mar2024 | ₹3.59 Cr |
| Mar2023 | ₹2.09 Cr |
| Mar2022 | ₹4.07 Cr |
How is Total Non-Current Liabilities of INDO US BIOTECH Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹0.56 Cr | -75.50 | |
| Mar2025 | ₹2.29 Cr | -36.14 | |
| Mar2024 | ₹3.59 Cr | 71.41 | |
| Mar2023 | ₹2.09 Cr | -48.61 | |
| Mar2022 | ₹4.07 Cr | - | |
Compare Total Non-Current Liabilities of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹136.5 Cr | -7.4% | -15.4% | -48% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹3,773.1 Cr | 0.5% | 3.2% | -30.4% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,298.2 Cr | -1.6% | -0.8% | 12.9% | Stock Analytics | |
| AVT NATURAL PRODUCTS | ₹1,343.8 Cr | -11.2% | -2.1% | 34.4% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹930.8 Cr | -12.1% | 2.8% | NA | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹562.6 Cr | 1.5% | 7.7% | 9.9% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | -7.4% |
-15.4% |
-48% |
| SENSEX | 0.6% |
-1.4% |
-10.7% |
You may also like the below Video Courses